ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
May 15, 2018
Disney’s Top Line Growing as It Leverages Film Successes
Image Source: David Holt. Media giant Disney has been executing well of late as it leverages its successful content into a broader scope of entertainment, but competition may be heating up related to its pending acquisition of Twenty-First Century Fox’s media assets.
May 14, 2018
Top 5 Burning Questions on Gilead Sciences
Image Source: Gilead Lab. We felt answers to a few burning questions pertaining to the abysmal first-quarter 2018 earnings release by Gilead Sciences would be of value to our readers. We are not in the least bit impressed by the earnings print, but we feel patience may be well rewarded. The Questions: 1. When will the decline in the Hepatitis C franchise abate? 2. Which new product will drive future revenue growth? 3. Will Cytokine Release Syndrome sink the potential of Yescarta? 4. How durable is Gilead's HIV franchise? 5. What else is in Gilead's pipeline?
May 14, 2018
Boeing’s Long-Term Strength Intact; Embraer Deal Nearing?
Image Source: Robert Sullivan. Boeing’s first-quarter report was highlighted by stable top-line growth, impressive bottom-line expansion, and increased full-year guidance. The long-term health of its business is supported by its massive backlog of unfulfilled deliveries.
May 11, 2018
Dividend Increases/Decreases for the Week Ending May 11
Let's take a look at companies that raised/lowered their dividend this week.
May 10, 2018
Omega’s First-Quarter Results Not Terrible; Dividend Still Intact
Image Source: Omega Healthcare, March 2018 presentation. Omega Healthcare is a healthcare real estate investment trust (REIT) that has been battling concerns within its customer base regarding rent payments. Just how healthy its customer line-up truly is will likely play out in coming years, but for now, management is leaving the dividend intact. Shares yield 9%+ at the time of this writing.
May 10, 2018
Soft Guidance Weighs on Booking Holdings Despite Solid First Quarter
Image Source: Luca Conti. You may have read this sentiment before: shares of Booking Holdings, formerly Priceline, are facing pressure following a solid quarterly report as management continued its habit of issuing conservative quarterly guidance.
May 10, 2018
Generic Drug Deflation Continues to Hamper Cardinal Health and AmerisourceBergen
Image Source: Aaron Fulkerson. A severe case of rampant generic drug deflation continues to hamper the share prices of Cardinal Health and AmerisourceBergen. We are monitoring the drug deflation numbers posted by the drug wholesalers as a key gauge of the investment merits of the group.
May 9, 2018
Realty Income Occupancy Highest in More Than a Decade
Image Source: Realty Income. Simulated Dividend Growth Newsletter portfolio idea Realty Income delivered a solid first quarter 2018 report that included impressive occupancy rates, steady adjusted funds from operations growth, and ongoing dividend expansion.
May 4, 2018
Dividend Increases/Decreases for the Week Ending May 4
Let's take a look at companies that raised/lowered their dividend this week.
May 3, 2018
Gilead Sciences at the Crossroads; HIV and Oncology Franchises Promising
Image Source: Gilead Sciences' first-quarter 2018 results. The loss of a key revenue-generating molecule is a tough, yet oftentimes manageable, portion of a pharma entity’s overall life cycle. Gilead Sciences is in the midst of a key turnaround as the loss of revenue from its Hepatitis C franchise is beginning to abate, while new novel treatments embark on the early stages of their respective revenue cycles. That said, we'd like to see traction in its HIV and oncology franchises, and perhaps the addition of a new franchise to the portfolio, or we will sour on the stock long-term.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.